JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
-2.39 (-1.66%)
At close: 4:00PM EDT

141.66 -0.19 (-0.13%)
After hours: 6:29PM EDT

Stock chart is not supported by your current browser
Previous Close144.24
Bid141.74 x 1000
Ask142.37 x 900
Day's Range140.76 - 143.85
52 Week Range120.11 - 148.99
Avg. Volume6,741,225
Market Cap376.62B
Beta (3Y Monthly)0.73
PE Ratio (TTM)26.29
EPS (TTM)5.40
Earnings DateJul 16, 2019
Forward Dividend & Yield3.80 (2.63%)
Ex-Dividend Date2019-05-24
1y Target Est149.17
Trade prices are not sourced from all markets
  • Pacira Gets EMA Acceptance for Pain Management Drug Exparel
    Zacks4 hours ago

    Pacira Gets EMA Acceptance for Pain Management Drug Exparel

    The EMA authorizes Pacira's (PCRX) marketing application for Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.

  • Will Democrats Slam Drug Prices? Health Care Stocks Dive Ahead Of Debate
    Investor's Business Daily6 hours ago

    Will Democrats Slam Drug Prices? Health Care Stocks Dive Ahead Of Debate

    Health care stocks floundered Wednesday ahead of the Democratic presidential debate and after President Donald Trump signed an order requiring hospitals to disclose their prices upfront.

  • Benzinga8 hours ago

    Morphic Holding IPO: What You Need To Know

    A biotech with licensing agreements with some of the big-name pharma companies such as AbbVie Inc (NYSE: ABBV ) and Johnson & Johnson (NYSE: JNJ )'s Janssen unit is testing the IPO waters this week. IPO ...

  • GuruFocus.com8 hours ago

    3 Top-Performing Large-Cap Stocks

    Analysts recommend Johnson & Johnson, Nestle and Visa

  • How JNJ and Gilead Are Working to Expand Their Portfolios
    Market Realist13 hours ago

    How JNJ and Gilead Are Working to Expand Their Portfolios

    According to Johnson & Johnson’s first-quarter earnings conference call, Erleada gained a four-percentage-point market share in the US on a YoY basis. The drug is now being prescribed equally by urologists and well as oncologists, the two key prescribers for prostate cancer drugs.

  • Here Are Johnson & Johnson’s Key Growth Drivers in Fiscal 2019
    Market Realist15 hours ago

    Here Are Johnson & Johnson’s Key Growth Drivers in Fiscal 2019

    Johnson & Johnson’s (JNJ) Pharmaceutical segment is the company’s key revenue driver and accounted for 51.17% of the company’s total revenues in the first quarter. Darzalex, Stelara, Tremfya, and Imbruvica reported double-digit YoY revenue growth in the first quarter.

  • Reuters16 hours ago

    Israeli health tech startup DayTwo raises $31 million

    Israel's DayTwo, which provides personalized nutritional insights based on intestinal bacteria, said on Wednesday it raised $31 million in private financing, bringing its total raised to $48 million. Existing investors Seventure Partners and Johnson & Johnson also participated. Its product uses gut profiling and other clinical parameters to enable individuals to choose specific foods to balance their blood sugar levels.

  • Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
    Zacks2 days ago

    Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $144.24, moving +0.82% from the previous trading session.

  • Axsome Initiates Phase III Study on Depression Candidate
    Zacks2 days ago

    Axsome Initiates Phase III Study on Depression Candidate

    Axsome (AXSM) initiates phase III GEMINI study of AXS-05 for the treatment of major depressive disorder.

  • What to Expect from Johnson & Johnson and Gilead Sciences’ EPS
    Market Realist2 days ago

    What to Expect from Johnson & Johnson and Gilead Sciences’ EPS

    In its first-quarter earnings press release, Johnson & Johnson (JNJ) has increased its fiscal 2019 adjusted diluted operational EPS guidance from the previously projected $8.65 to $8.80, which implies YoY growth of 5.7%–7.6%, to $8.73–$8.83, which implies a YoY rise of 6.7%–7.9%. The company also increased the lower end and narrowed its fiscal 2019 adjusted diluted EPS guidance from $8.50–$8.65.

  • How Are Johnson & Johnson’s Revenues Trending in 2019?
    Market Realist2 days ago

    How Are Johnson & Johnson’s Revenues Trending in 2019?

    In its first-quarter earnings conference call, Johnson & Johnson (JNJ) forecasted a stronger operational revenue growth outlook and expects YoY adjusted operational sales growth of 2.5% to 3.5% and operational sales growth of 0.5% to 1.5% for fiscal 2019. The company has also guided for a YoY reported sales decline of 1.5% to 0.5% for fiscal 2019 based on the euro spot rate of $1.12.

  • What Are Analysts Recommending for Johnson & Johnson and Gilead?
    Market Realist2 days ago

    What Are Analysts Recommending for Johnson & Johnson and Gilead?

    Johnson & Johnson (JNJ) is up by 10.10%, and Gilead Sciences (GILD) is up by 10.92% on a YTD basis. Both the companies are struggling due to intense competitive pressures either from branded or generic competitors. The consensus recommendation for both Johnson & Johnson and Gilead Sciences is a “buy.”

  • MoneyShow2 days ago

    An Argus Research Portfolio for Sustainable Impact Stocks

    Sustainable Impact investing is gaining traction not only with our clients, but also with the global investment community, observes John Eade, an analyst with Argus Research, a leading independent Wall Street research firm.

  • Moody's3 days ago

    LifeScan Global Corporation -- Moody's announces completion of a periodic review of ratings of LifeScan Global Corporation

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of LifeScan Global Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Oklahoma judge approves Teva's $85 million opioid settlement
    Reuters3 days ago

    Oklahoma judge approves Teva's $85 million opioid settlement

    The decision by Cleveland County District Judge Thad Balkman in Norman, Oklahoma came after the state's attorney general, governor and top lawmakers resolved a dispute over how the money should be deposited and spent. Oklahoma Attorney General Mike Hunter struck an initial settlement with Teva on May 26, just days before the Israel-based drugmaker was set to face trial alongside Johnson & Johnson, which is continuing to fight the case. The settlement resolved claims that Teva and other drugmakers helped cause the epidemic by marketing opioids as safe and effective for everyday pain while downplaying their addictive qualities.

  • 3 Top Healthcare Stocks to Buy Right Now
    Motley Fool3 days ago

    3 Top Healthcare Stocks to Buy Right Now

    These three healthcare stocks could be outstanding additions to your portfolio.

  • How Chinese Culture Could Affect the Future of 3M Stock
    InvestorPlace3 days ago

    How Chinese Culture Could Affect the Future of 3M Stock

    3M (NYSE:MMM) stock price has begun to recover from one of the more significant drops in company history. An earnings miss related to the trade war and speculation about the security of the dividend of 3M stock have hammered the shares.Source: Shutterstock Both factors have added significant risk to a company most regard as stable. Although 3M stock price should recover, unusual risk factors make MMM stock suitable for only income-oriented, risk-tolerant investors. * 7 Top S&P 500 Stocks of 2019 (So Far) Threats to 3M's Dividend Hit 3M stockIn late April, 3M stock price went into free-fall following a massive earnings miss. The stock plunged by about 13% following the announcement. Warnings about the stability of the company's dividend caused MMM stock further pain.InvestorPlace - Stock Market News, Stock Advice & Trading TipsLast month, analyst Stephen Tusa of JPMorgan Chase (NYSE:JPM) kept his "underweight" rating on 3M stock and took his price target on MMM stock down to $143 per share. He also warned that the company could cut its dividend. Tusa's note led to a further decline in 3M stock price over the next month. The drop would take MMM stock from a high of almost $220 per share to a low just above $159 per share.Any time analysts talk about the end of a 60-year streak of dividend increases, it is a serious matter. Such an action could bring years of devastation and stagnation to 3M stock.For now, traders have shrugged off the underweight rating. Just three weeks after hitting its 52-week low, the 3M stock price has risen to nearly $174 per share. 3M Is a ConglomerateIf only scotch tape and post-it notes held this company together, I would be wary of the move higher by 3M stock. However, much like another well-known conglomerate named Johnson & Johnson (NYSE:JNJ), 3M's products extend across several divisions and industries. Health Care, 3M's only division to report revenue growth last quarter, will likely receive a boost from the company's recent $6.7 billion acquisition of Acelity.Still, this diversification does not make 3M stock bulletproof. All one has to do is study the decline of General Electric (NYSE:GE) to know that older industrial conglomerates can face devastation and even fail. I see Tusa's call on the dividend as extreme. However, if the U.S.-China trade war persists long enough, the dividend could be cut. Do Not Forget the Trade War, Culture RiskIt is the trade war that I see as the most significant risk to 3M stock. The Asia-Pacific region, which includes both China and Japan, accounted for 31.3% of 3M's overall revenue in 2018. The trade war has lasted longer than almost anyone thought it would.Investors also need to consider cultural factors that statistics cannot quantify. China's President, Xi Jinping, basically runs China as a dictatorship. While an end to the trade war would benefit both the Chinese people and 3M stock, dictators often act contrary to their people's interest.Another factor involves Chinese culture itself. The Chinese consider saving face quite important. This makes China unlikely to sign a trade deal that will make it appear to be the loser. As a result, not only must U.S. negotiators sign an agreement that works for America, but they must also create an arrangement that at least appears to benefit the Chinese.This creates a conundrum for the owners of 3M stock, as such a deal could happen tomorrow, two years from now, or perhaps never. Still, I see reasons to buy MMM stock for those who can handle risk. The current price-earnings ratio of 3M stock is 18.5, which is below the historical average of 23.2. Moreover, most analysts believe the company's earnings will resume growing next year, although their profit estimates likely factor in an end to the trade war.Further, thanks to the decline of 3M stock price, 3M's dividend yield now stands at about 3.3%. 3M pays out 58.6% of its income in dividends. If that percentage moves closer to 100%, the payout would be endangered. However, 3M has some cushion before it has to resort to ending its streak of payout hikes. Final Thoughts on 3M Stock3M stock carries culture-based risk which investors rarely consider. Consequently, MMM stock best suits investors who can tolerate risk and need income. JPMorgan's Tusa may have exaggerated the threat to 3M's dividend. Nonetheless, the trade war appears unlikely to end soon, and China accounts for a large percentage of 3M's revenues.But complicating an end to the trade war is China itself. Due to 3M's dependence on China, the future of 3M depends heavily on a dictator who's intent on saving face. This factor could make 3M stock riskier than it's ever been.MMM stock pays a generous, growing dividend. It also trades at a low multiple. However, with the future of the stock hanging on geopolitics and Chinese culture, only those willing to deal with those risk factors should buy the shares.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Telecom Stocks to Set on Speed Dial * 6 Stocks to Sell in the Back Half of 2019 * 7 Top S&P 500 Stocks of 2019 (So Far) Compare Brokers The post How Chinese Culture Could Affect the Future of 3M Stock appeared first on InvestorPlace.

  • Benzinga3 days ago

    Minerva Spikes Higher After Novel Insomnia Drug Aces Mid-Stage Trial

    Shares of thinly traded micro-cap biotech Minerva Neurosciences Inc (NASDAQ: NERV ) spiked higher on Monday. What Happened Minerva announced results of a Phase 2b study that evaluated its seltorexant, ...

  • 3 Excellent Dividend Aristocrats You Can Buy Right Now
    Motley Fool3 days ago

    3 Excellent Dividend Aristocrats You Can Buy Right Now

    These quality businesses have lots of opportunities to keep raising what they give back to investors.

  • Financial Times3 days ago

    The rise of the anti-vaxxers is bad news for business

    If tariffs and trade wars were not enough to worry about, businesses around the world are faced with a new threat: outbreaks of childhood infections like measles. The measles virus is much the same worldwide. The causes of these public health crises are not.

  • Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma
    Zacks6 days ago

    Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma

    The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.

  • Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
    Zacks6 days ago

    Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

  • 5 Boring Stocks to Buy This Summer
    InvestorPlace7 days ago

    5 Boring Stocks to Buy This Summer

    It's summertime and the living is easy. Or at least it should be. These days, volatility is getting pretty crazy. While the Federal-Reserve-induced swings have been moving the market higher, it was just a few weeks ago that trade issues were sending stocks lower. This sort of extreme ebb and flow is not exactly the kind of environment that breeds restful nights of sleep. This is especially true if you are near or in retirement.That is unless you focus on boring stocks.Perhaps the best stocks to buy this summer are the ones you don't have to think about. We're talking about boring stocks that generate good revenues in good times and in bad. Nothing too flashily. No crazy exposure or reliance on trendy sectors of the market. Moreover, these stocks reward investors with plenty of dividends and buybacks. You can simply buy shares, collect your income and just forget about them.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn the end, with volatility surging and the markets moving in a big way, the stocks to buy this summer are the boring ones. It's the best strategy to get through and not get seasick. * 10 'Buy-and-Hold' Stocks to Own Forever With that said, here are five boring stocks to buy this summer. Johnson & Johnson (JNJ)Source: Shutterstock One of the best stocks to buy this summer could be Johnson & Johnson (NYSE:JNJ). When it comes to the healthcare sector, there's no bigger blue chip than JNJ. The firm's empire spans more than 250 operating companies across a variety of healthcare subsectors. That includes consumer healthcare products and medical devices to advanced oncology and immunology drugs. JNJ really does it all.And doing it all makes it a pretty boring stock as well.Thanks to JNJ's multiple product lines, the firm has been able to navigate some tough economic markets over the course of its history. When one of its product lines is suffering, another can pick up the slack. And the fact that JNJ sells its products in more than 60 countries is the icing on the cake. The firm's adjusted earnings have continued to increase for over 35 years based on its deep product line. Moreover, it has been able to increase its dividend for the last 57 years straight. Currently, Johnson & Johnson yields 2.71%. That's a very impressive track record that allows it to keep going during times of duress.Now, there is some new risk at JNJ, such as it's own going talc issues as well as a new pending opioid lawsuit. But even here, JNJ's size and scope will help it navigate with relative ease.All in all, JNJ could one of the best stocks to buy this summer. Republic Services (RSG)Source: Shutterstock According to the latest EPA survey, Americans generate more than 254 million tons of trash or recyclables per year. That's a lot of garbage. But for Republic Services (NYSE:RSG), that trash is a gold mine.RSG is one of the largest trash haulers in the nation. That position provides it plenty of scales. And scale is important in the garbage industry. The problem is that hauling garbage is a relatively low-margined business. By having that scale, Republic is able to earn a little from all its operations. Moreover, it's able to undercut most smaller mom and pop operators for winning key job bids. This base of operations, as well as ownership of its own landfills, has allowed RSG to quickly become a dividend champion -- growing its payout by an average of 8% over the last three years.But RSG is finding ways to boost its potential as well.That includes boost higher-margined recyclable hauling as well as expanding into other areas of waste disposal. Republic now owns several saltwater disposal wells from the oil and gas industry and has moved into providing renewable energy. Turns out, landfills throw off plenty of natural gas that can be burned for energy production, while several of its sites are prime candidates for solar and wind power. * 7 Blue-Chip Stocks to Buy for a Noisy Market Trash is boring, but RSG is turning that boring nature into gold. Southern (SO)Source: Shutterstock The stocks to buy this summer could be the utilities. Perhaps nothing more boring than those firms that produce electricity, water, and natural gas. That includes top-notch utility Southern (NYSE:SO). SO is one of the largest-regulated utilities in the nation and provides power to more than 9 million customers across several states. This provides SO with plenty of steady cash flows that continue to fuel its growth and shareholder rewards.The firm has paid dividends since the 1950's and has raised its payout over the last 17 years straight.Fueling that dividend growth has been the unregulated side of its businesses. A few years ago, Southern purchased pipeline and gas supplier AGL Resources. A similar buy of gas supplier NICOR followed. This moved Southern into the pipeline industry. It turns out this was a great decision. While the combination of FERC-regulated pipelines as well as unregulated gathering/trunk lines have helped boost SO's overall profits since the buyouts.Southern isn't without its warts. The firm has continued to struggle with carbon capture projects and has taken a bath on its nuclear plants thanks to cost overruns and bankruptcy of its contractor Westinghouse. This has pressured the firm in recent quarters.However, the vast bulk of Southern is good, old-fashioned and boring power generation. And because of that, SO makes a great stock to buy for its high 4.6% yield this summer. Chubb (CB)Source: Pictures of Money via FlickrI think I'd rather watch paint dry than talk about the insurance industry. But when it comes to the boring stocks to buy, the insurance sector is often top-notch. The sector is able to make plenty of bank on its underwriting and the delicious float from its investments. One of the best could be insurer Chubb (NYSE:CB).CB is a multi-line insurer and has operations that span pretty much every sub-category of insurance. This includes property and casualty, accident and health, reinsurance, and life insurance. Chubb does it all and it does so across the globe.What's great about that multi-line approach is the CB is surprisingly profitable. Chubb takes a real hands-on approach to its underwriting- especially when it comes to reinsurance and insuring property/casualty lines for businesses. This has allowed it to have an amazing average combined ratio- a key metric of profitability in the insurance industry- that has come in 8.7 percentage points lower than many of its rivals over the last ten years. When you add in profits from its float investments, you have a real winner on your hands.This has continued to drive CB's dividend over its history. The firm has managed to raise its payout over the last 26 years straight. This includes a recent 3% bump at the beginning of the summer. With continued float gains and smart underwriting, Chubb should continue to keep the gains coming. * 7 Fantastic Fidelity Funds for a Range of Investors For investors, insurance is as boring as they come. But Chubb makes a great stock to buy for years of steady gains. Mondelez International Inc (MDLZ)Source: Shutterstock It turns out, the boring world of cookies, crackers and chewing gum provides perfect ballast to the market's gyrations. That's wonderful news for former Kraft-Heinz (NYSE:KHC) spin-out Mondelez International (NYSE:MDLZ).MDLZ features some of the world's biggest brands in snack foods like Oreo's, Nabisco and Cadbury candy. What's great is that snack foods blend the line between being a staple and discretionary item. This allows them to have slightly higher margins than say, toilet paper. However, demand for these sorts of items stays pretty steady. Better still is that MDLZ is able to pass on price increases relatively easy onto consumers. This has helped boost DLZ's results in recent quarters.But Mondelez has plenty of growth in the tank as well. The firm has continued to expand into higher-margined healthy snacks as well as emerging markets. And the firm has started to seriously consider adding cannabis to many of its foods as legalization approaches. Given its huge brand portfolio, this could be a major revenue driver in the future.With a great combination of steady-like demand and plenty of growth potential, MDLZ could be a wonderfully boring stock to buy for this summer.As of this writing, Aaron Levitt did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Blue-Chip Stocks to Buy for a Noisy Market * 5 Strong Buy Biotech Stocks for the Second Half * 6 Stocks Ready to Bounce on a Trade Deal Compare Brokers The post 5 Boring Stocks to Buy This Summer appeared first on InvestorPlace.

  • GuruFocus.com7 days ago

    The Value of Best-in-Class Management

    Some thoughts on the importance of an extraordinary CEO

  • Bloomberg8 days ago

    Billions at Stake in Opioid Suits, But It's No Tobacco Windfall

    (Bloomberg) -- An Oklahoma case, the first of more than 1,600 lawsuits filed by U.S. state and local governments against opioid makers to go to trial, could serve as a key benchmark for governments hoping to recoup costs associated with the public health crisis.However, verdicts and legal settlements resulting from the litigation are likely to be smaller than the 1998 global settlement with tobacco companies and won’t significantly affect government budgets, according to Fitch Ratings.The tobacco settlement with 46 states compensated them with more than $200 billion for decades of tobacco-related health-care costs, but wasn’t enough to alter state and local government credit quality, according to Fitch. The opioid epidemic has taken place over a shorter time span, and hasn’t resulted in as many deaths, according to Marcy Block, a Fitch analyst.“It’s severe, but it’s less if you think about the amount of deaths through tobacco usage,” Block said.Ten TimesMore than 47,000 Americans died from opioid overdoses in 2017, including heroin and fentanyl, a synthetic opioid, according to the National Institute on Drug Abuse. Cigarette smoking is responsible for ten times as many deaths annually, according to the Centers for Disease Control and Prevention.Oklahoma sued Johnson & Johnson, Purdue Pharma LP and Teva Pharmaceutical Industries Ltd. in 2017, alleging the companies deceived the public by overstating the benefits of their drugs while downplaying the risk of addiction. Teva in May agreed to pay $85 million to resolve the suit. Purdue Pharma, the maker of OxyContin, agreed in March to pay $270 million.Read more about how opioid makers are getting squeezed as cities try to form a negotiating groupThe opioid litigation could cost the pharmaceutical industry between $5 billion and $50 billion, based on the 1998 tobacco deal and costs of the abuse epidemic, according to Bloomberg Intelligence analyst Holly Froum. Oklahoma is seeking at least $10 billion in damages and penalties for current and future outlays from Johnson & Johnson.“The depth of evidence against the opioid manufacturers, including any potential evidence of fraudulent marketing, will be a key determinant not only of how this case is decided, but the thousands of additional cases against the industry, “ wrote Rachel Barkley, a senior vice president at Loop Capital Markets earlier this month.“Additionally, the size of any settlement would likely serve as a benchmark in future cases,” she said.Securtitized ProceedsStates and local governments issued tens of billions of dollars in muni bonds backed by the tobacco settlement and some used that money to plug budget gaps. The securities are repaid with the money they receive each year from cigarette companies under the settlement. The amount of the payments is based on annual cigarette shipments. There are currently $85 billion of tobacco bonds outstanding, including debt issued to refinance previously issued securities.At least 42 states and more than 1,900 municipalities have sued opioid manufactures and distributors, blaming them for creating a national public-health crisis and demanding billions of dollars in damages.A U.S. federal judge in Cleveland is overseeing opioid litigation brought by U.S. cities and counties and has set two trials for October. The scope of the litigation could result in a global settlement that mimics the resolution to the tobacco cases in the 1990s.The CDC estimates that the total “economic burden” of prescription opioid misuse alone in the U.S. is $78.5 billion a year, including the costs of health care, lost productivity, addiction treatment and criminal justice involvement.Factoring the economic value of lives lost, the White House’s Council of Economic Advisers estimated the costs of the epidemic in 2015 totaled $504 billion.Related: States Are Suing Opioid Makers But Their Pensions Embrace ThemTo contact the reporter on this story: Martin Z. Braun in New York at mbraun6@bloomberg.netTo contact the editors responsible for this story: James Crombie at, Michael B. Marois, Shannon D. HarringtonFor more articles like this, please visit us at©2019 Bloomberg L.P.